Biomarker Leadership MedQIA leads in imaging biomarker science for clinical trials, offering multidisciplinary expertise in imaging physics, computer vision, biostatistics, and radiological sciences to accelerate biomarker development and trial endpoints.

Full CRO Capabilities As a global full-service CRO, MedQIA handles end-to-end clinical trial support from planning to completion, with a specialty in quantitative imaging biomarkers for Phase I through IV studies to attract sponsors seeking integrated imaging solutions.

Clinical Operations Edge Competitive advantage stems from a responsive Clinical Operations team combined with clinicians and scientists across imaging, oncology, radiology, and biostatistics, enabling faster trial timelines and cohesive cross-functional delivery.

Tech and Data Focus Leverage advanced computer-aided image interpretation and analysis capabilities to offer objective endpoints, potential cost efficiencies, and standardized imaging workflows that align with pharma and device development programs.

Growth and Fit Current revenue range indicates room for scale; target mid-to-large sponsors in need of imaging biomarker integration, especially those with oncology portfolios, to expand MedQIA’s footprint among benchmark CROs with specialized imaging capabilities.